Thierry Verbinnen

1.4k total citations
39 papers, 1.0k citations indexed

About

Thierry Verbinnen is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Thierry Verbinnen has authored 39 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hepatology, 32 papers in Epidemiology and 14 papers in Infectious Diseases. Recurrent topics in Thierry Verbinnen's work include Hepatitis C virus research (36 papers), Hepatitis B Virus Studies (30 papers) and Liver Disease Diagnosis and Treatment (16 papers). Thierry Verbinnen is often cited by papers focused on Hepatitis C virus research (36 papers), Hepatitis B Virus Studies (30 papers) and Liver Disease Diagnosis and Treatment (16 papers). Thierry Verbinnen collaborates with scholars based in Belgium, United States and France. Thierry Verbinnen's co-authors include Oliver Lenz, Leen Vijgen, Kenneth Simmen, Tse‐I Lin, Gregory Fanning, Sandra De Meyer, Bart Fevery, Annick Scholliers, Pierre Raboisson and Katrien Vermeiren and has published in prestigious journals such as Gastroenterology, Journal of Virology and Gut.

In The Last Decade

Thierry Verbinnen

37 papers receiving 1.0k citations

Peers

Thierry Verbinnen

HEPAT

EPIDE

RHEUM

A Howe United States

Hyunsoon Kang United States

Ross Martin United States

Isla Humphreys United Kingdom

Yuao Zhu United States

Sue Ma United States

Betsy J. Eggers United States

Ann M. Tigges United States

Lotte S. Mikkelsen Denmark

Kevin A. Pokornowski United States

A Howe United States

Thierry Verbinnen

878 ×1.0

HEPAT

754 ×0.9

EPIDE

434 ×1.1

87 ×1.0

54 ×0.9

RHEUM

Citations per year, relative to Thierry Verbinnen Thierry Verbinnen (= 1×) peers A Howe

Countries citing papers authored by Thierry Verbinnen

Since Specialization

Citations

This map shows the geographic impact of Thierry Verbinnen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Verbinnen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Verbinnen more than expected).

Fields of papers citing papers by Thierry Verbinnen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Verbinnen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Verbinnen. The network helps show where Thierry Verbinnen may publish in the future.

Co-authorship network of co-authors of Thierry Verbinnen

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Verbinnen. A scholar is included among the top collaborators of Thierry Verbinnen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Verbinnen. Thierry Verbinnen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gane, Edward, Ewa Janczewska, Tetsuo Takehara, et al.. (2025). Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study. JHEP Reports. 7(10). 101516–101516. 1 indexed citations

Bömmel, Florian van, Thierry Verbinnen, Kosh Agarwal, et al.. (2025). Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B.. PubMed. 9(3).

Kennedy, Patrick, Gürdal Yılmaz, Wan‐Long Chuang, et al.. (2025). Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study. Gut. gutjnl–2025.

Agarwal, Kosh, Marı́a Buti, Florian van Bömmel, et al.. (2024). JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology. 81(3). 404–414. 22 indexed citations

Asselah, Tarik, Scott Fung, Sıla Akhan, et al.. (2024). OS-033 A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos (t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B-Interim results of the OCTOPUS-1 study. Journal of Hepatology. 80. S27–S28. 2 indexed citations

Janssen, Harry L.A., Jinlin Hou, Tarik Asselah, et al.. (2023). Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut. 72(7). 1385–1398. 31 indexed citations

Verbinnen, Thierry, Willem Talloen, Harry L.A. Janssen, et al.. (2023). Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study. Antiviral Research. 216. 105660–105660. 4 indexed citations

Slaets, Leen, Filip De Ridder, Oliver Lenz, et al.. (2020). Systematic review with meta‐analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy. 2(3). 106–116. 3 indexed citations

Verbinnen, Thierry, Willem Talloen, Jan Martin Berke, et al.. (2020). Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy. Journal of Viral Hepatitis. 27(11). 1127–1137. 14 indexed citations

10.

Zoulim, Fabien, Oliver Lenz, Joris Vandenbossche, et al.. (2020). JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 159(2). 521–533.e9. 85 indexed citations

11.

Zoulim, Fabien, Christophe Moreno, Samuel S. Lee, et al.. (2018). A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. Virology Journal. 15(1). 26–26. 6 indexed citations

12.

Berke, Jan Martin, Thierry Verbinnen, Pascale Dehertogh, et al.. (2017). Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro. Antiviral Research. 144. 205–215. 25 indexed citations

13.

Wei, Lai, Tao Han, Dongliang Yang, et al.. (2016). Simeprevir plus peginterferon/ribavirin for HCV genotype 1‐infected treatment‐naïve patients in China and South Korea. Journal of Gastroenterology and Hepatology. 31(5). 912–920. 7 indexed citations

14.

Sarrazin, Christoph, Erkki Lathouwers, Monika Peeters, et al.. (2015). Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Research. 116. 10–16. 82 indexed citations

15.

Reddy, K. Rajender, Stefan Zeuzem, Fabien Zoulim, et al.. (2014). Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. The Lancet Infectious Diseases. 15(1). 27–35. 44 indexed citations

16.

Lenz, Oliver, Thierry Verbinnen, Bart Fevery, et al.. (2014). Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. Journal of Hepatology. 62(5). 1008–1014. 110 indexed citations

17.

Lenz, Oliver, Joep de Bruijne, Leen Vijgen, et al.. (2012). Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy. Gastroenterology. 143(5). 1176–1178.e6. 31 indexed citations

18.

Lenz, Oliver, Joep de Bruijne, Leen Vijgen, et al.. (2011). 1221 TREATMENT OUTCOME AND RESISTANCE ANALYSIS IN HCV GENOTYPE 1 PATIENTS PREVIOUSLY EXPOSED TO TMC435 MONOTHERAPY AND RE-TREATED WITH TMC435 IN COMBINATION WITH PEGIFNα-2A/RIBAVIRIN. Journal of Hepatology. 54. S482–S483. 7 indexed citations

19.

Lin, Tse‐I, Oliver Lenz, Gregory Fanning, et al.. (2009). In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. Antimicrobial Agents and Chemotherapy. 53(4). 1377–1385. 142 indexed citations

20.

Raboisson, Pierre, Oliver Lenz, Tse‐I Lin, et al.. (2007). Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(7). 1843–1849. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact